Drug news
Takeda returns rights to ferumoxytol to Amag Pharma.
Takeda Pharmaceuticals has handed back marketing rights to Amag Pharmaceuticals for the anemia treatment ferumoxytol. Under the termination agreement, Amag will regain all development and commercialization rights for the product. Takeda will make a termination payment to Amag and will provide certain transition services to Amag for up to 180 days after the marketing authorization transfer in each territory.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.